Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRO-002 in Advanced Ovarian and Endometrial Cancer
NCT03748186Phase 1Completed
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Feb 2019
- Primary completion
- Jun 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of luveltamab tazevibulin in ovarian cancer and endometrial cancer (EC), sponsored by Sutro Biopharma, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 18 months, Recommended Phase 2 Dose at 18 months and 3 more. Started Feb 2019; status: completed.
02
Drugs
luveltamab tazevibulin
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03748186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748186.